
Similar Posts

Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.

We’ve seen 18% year-over-year volume growth driven by e-commerce, says Payoneer CEO John Caplan
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell: Overtime John Caplan, Payoneer CEO, joins ‘Closing Bell Overtime’ to talk consumer spending behavior heading into 2024. 03:17 Fri, Dec 29 20236:13 PM EST

China seems to think that it is ‘out of the woods’: Professor
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Edmund Phelps of Columbia University says China seems to think that it has solved its problems, and its economy will see a return to “somewhat higher” growth rates. He also says China could “break loose” with a long wave of rapid innovation….

Small businesses are continuing to worry about wage growth, says U.S. Chamber of Commerce CEO
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Squawk on the Street Suzanne Clark, U.S. Chamber of Commerce CEO, joins ‘Squawk on the Street’ to discuss the state of American business. 05:07 2 hours ago

You’ll see very strong earnings from General Motors on Tuesday, says Benchmark’s Ward
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Michael Ward, The Benchmark Company auto analyst, and Garrett Nelson, CFRA senior auto analyst, join ‘Power Lunch’ to discuss the bull case for General Motors and Ford, Nelson’s thoughts on Ford in the mid- to long-term and more. 04:32 Mon, Oct 24…

Jim Cramer breaks down JPMorgan’s Stanley Black & Decker downgrade
‘Mad Money’ host Jim Cramer breaks down JPMorgan’s reasoning for downgrading Stanley Black & Decker